沙立度胺联合VAD方案治疗初发多发性骨髓瘤疗效观察  

Clinical efficacy of Thalidomide combined VAD regimen in the treatment multiple myeloma

作　　者：刘蕴华 

机构地区：[1]河南省信阳市中心医院血液科,464000

出　　处：《中国实用医药》2011年第27期42-43,共2页China Practical Medicine

摘　　要：目的观察沙立度胺联合VAD方案治疗初发多发性骨髓瘤(MM)患者的临床疗效和不良反应。方法选择35例初发多发性骨髓瘤患者,采用沙立度胺联合VAD方案进行化疗,每一个疗程为21d,每个疗程之后间歇4周,治疗3个疗程后观察临床疗效及药物的毒副反应。结果治疗3个疗程后,5例患者完全缓解,19例患者部分缓解,进步5例、总有效率为82.8%。毒副反应为骨髓抑制,指端麻木及便秘等。结论沙立度胺联合VAD方案治疗初发MM患者疗效较好,不良反应可以耐受,值得临床推广。Objective To observe the clinical curative effect and toxicity of drugs of Thalidomide combined VAD regimen on treating newly diagnosed multiple myeloma （MM） patients. Methods 35 patients with newly diagnosed MM treated with Thalidomide combined VAD regimen. Every 21 days a course of treatment, intermittent 4 weeks after treatment, observation of efficacy and toxicity of drugs. Results After treatment for 3 treatments, among the 35 patients,5 patients achieved complete remission（CR） and 19 partial remission（ PR）, 5 patients improved and the total effective rate was 82. 8%. Drug toxicity were bone marrow suppression, fingertip numbness and constipation etc. Conclusion Treating newly diagnosed multiple myeloma （MM） patients with Thalidomide combined VAD regimen can obtain a better efficacy, which is effective, safe, well-tolerable and worth to practice in clinics.

关 键 词：沙立度胺 VAD方案 多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]